An Observational Study to Assess the Prevalence and Outcomes of Primary Pulmonary Coccidioidomycosis in Persons Aged > / = 14 Years Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (SAnds-PPC)

Completed

Conditions studied: Coccidioidomycosis, Pneumonia

In brief

This is an observational study in 750 individuals aged 14 years or older, diagnosed with Community Acquired Pneumonia (CAP) who meet all eligibility criteria in Coccidioides endemic regions. This study is designed to provide data on the prevalence of primary pulmonary coccidioidomycosis among persons presenting with CAP in endemic regions. Among individuals diagnosed with primary pulmonary coccidioidomycosis, we aim to describe the clinical course, predictors of the clinical course and compare the response to prescribed antifungal therapy versus no antifungal therapy. The hypothesis for patients with primary pulmonary coccidioidomycosis is that early treatment with antifungal therapy is effective in reducing the frequency, severity and associated adverse outcomes of infection with recently acquired coccidioidomycosis pneumonia. The study will be divided into Step 1 and Step 2. Step 1 will identify which subjects have primary pulmonary coccidioidomycosis based on the case definition for the protocol and Step 2 will follow subjects who meet the case definition and will observe their clinical management and clinical outcomes. Subjects will enroll in Step 1 within 28 days of symptom onset. In Step 1, blood work for serologic determination of Coccidioides infection will be drawn at the time of enrollment (Day 1), and again 21 days later if a positive result is not reported at Day 1. Subjects with a diagnosis of primary pulmonary coccidioidomycosis confirmed by positive serologic testing during Step 1 will enter Step 2 within 21 days of a positive test result; subjects with a negative serology at Day 1 and Day 22 will not be followed further. Subjects referred to the study after a diagnosis of primary pulmonary coccidioidomycosis confirmed by positive serologic testing will also be allowed to enter Step 2 directly within 21 days of a positive test result and within 7 weeks of symptom onset, as long as they meet study enrollment criteria. The primary objective is to assess the prevalence of primary pulmonary coccidioidomycosis (PPC) in subjects with community acquired pneumonia (CAP) in coccidioidomycosis endemic areas.

Key facts

Study ID: NCT03908632
Run by: National Institute of Allergy and Infectious Diseases (NIAID)
People needed: 651
Starts: 2019-02-14
Expected to finish: 2023-12-05
Last updated by the study team: 2024-01-19

Who can join

Age: 14 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Step 1 Subject Inclusion Criteria:
Aged > / = 14 years and presenting for clinical care in coccidioidomycosis endemic areas.
Diagnosis of community acquired pneumonia (CAP) established by a health care provider.
Pulmonary opacity on chest X-ray or computerized tomography (CT) scan consistent with CAP.
Onset of symptoms related to current CAP diagnosis within 28 days prior to enrollment.
Must be able to understand the study and provide informed consent.*
If aged < 18 years, the parent(s) or guardian must be able to understand the study and provide informed consent, with the assent of the minor.
Willing and able to comply with study procedures and complete study visits.
Willing to allow access to medical records, and medical records are available to the study team.
Step 2 Subject Inclusion Criteria:
Aged > / = 14 years
Presence of at least one influenza-like sign or symptom (e.g. fever, chest pain, cough, myalgia, arthralgia, and headache.
Onset of any symptoms no earlier than 7 weeks prior to enrollment into Step 2.
Opacity/pleural effusion diagnosed by chest radiograph or computerized tomography (CT) scan .
Positive result for any serologic test confirming coccidioidomycosis obtained within 21 days prior to enrollment into Step 2.*
The assays considered for this criterion are: coccidioidal immunoglobulin M (IgM) by immunodiffusion, enzyme immunoassay (EIA), latex agglutination or tube precipitin OR coccidioidal immunoglobulin G (IgG) by immunodiffusion, EIA, or complement fixation. The interpretation of positive or negative is per the reporting laboratory instructions
Must be able to understand the study and provide informed consent.**
*If aged <18 years, the parent(s) or guardian must be able to understand the study and provide informed consent, with the assent of the minor.
Willing and able to comply with study procedures and complete study visits.
Willing to allow access to medical records, and medical records are available to the study team.

You may not qualify if…

Step 1 Subject Exclusion Criteria:
Have documented microbiologically- or serologically-confirmed past infections with Coccidioides.*
An initial positive serologic test obtained within 21 days inclusive prior to enrollment is permissible.
Hospitalization within 14 days prior to the onset of pneumonia symptoms.
Presence of cavitary lung disease.
Evidence of disseminated, extrathoracic disease.
Step 2 Subject Exclusion Criteria:
Have documented microbiologically- or serologically-confirmed past infections with Coccidioides.*
An initial positive serologic test obtained within 21 days inclusive prior to enrollment is permissible.
Presence of cavitary lung disease.
Evidence of disseminated, extrathoracic disease.

Where it is running

Banner - University Medical Center Advanced Lung Disease Clinic - Phoenix — Phoenix, Arizona, United States
The University of Arizona - Banner University Medical Center Tucson Campus - Tucson — Tucson, Arizona, United States
Kaiser Permanente Chester Avenue Medical Offices - Pulmonology — Bakersfield, California, United States
Kern Medical Center — Bakersfield, California, United States
UCSF Fresno Center for Medical Education and Research - Clinical Research Center — Fresno, California, United States
Kaiser Permanente Antelope Valley Medical Offices - Infectious Diseases — Lancaster, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.